News
An invention patent has been authorized by the National Intellectual Property Administration.
Date:
01 Mar,2021
On August 21, a patent invention from Wanbangde Pharmaceutical was authorized by the National Intellectual Property Administration. The patent, titled "A Pharmaceutical Composition of Norfloxacin and Its Preparation Method," bears the patent number ZJ201510829464.8.
For years, the company's R&D center has been dedicated to researching key process technologies and innovative drugs. By continuously strengthening industry-academia-research collaborations and establishing robust communication mechanisms among these partners, we are fully leveraging the resource advantages of pharmaceutical universities, research institutions, and leading hospitals—ultimately advancing our drug development efforts to align with global standards in areas such as safety evaluation, quality control, manufacturing processes, clinical studies, and formulation technology innovation.
This patented invention represents years of research and development by Wanbangde Pharmaceutical, during which numerous challenges were overcome through rigorous experimentation. The result is a successful formulation of a norfloxacin drug composition along with its innovative preparation method. The composition contains an effective amount of norfloxacin combined with pharmaceutical excipients, with the active ingredient accounting for 50% to 80% of the total formulation. The excipients used for pellet formation include microcrystalline cellulose, powdered cellulose, low-substituted hydroxypropyl cellulose, or corn starch—either individually or in combination. Additionally, the invention provides a detailed method for preparing the norfloxacin drug composition: first, a drug-containing core is produced via extrusion and spheronization, followed by film-coating before being filled into capsules. This innovative norfloxacin formulation not only allows precise control over the dissolution rate of the oral dosage form but also significantly enhances the stability of the final product. This patent underscores the company’s commitment to fostering a robust science and technology innovation incentive system, driving continuous advancements in corporate R&D and technological breakthroughs. Ultimately, it helps maintain the company’s cutting-edge technological edge while boosting its overall scientific and technical capabilities—and strengthening its core competitive advantage in the industry.
In recent years, Wanbangde Pharmaceutical has continuously achieved new breakthroughs in pharmaceutical technology innovation. The company has established a provincial-level academician expert workstation, a provincial enterprise research institute specializing in cardiovascular and cerebrovascular drugs, and the Ginkgo Leaf Droplet Pill Medical-Research-Enterprise Collaborative Innovation Alliance. Additionally, it has brought in top-tier expertise—joining forces with Academician Tang Xican of the Chinese Academy of Engineering and his team, as well as Academician Wang Guangji and their respective teams—to drive the company’s cutting-edge drug development efforts and elevate its overall R&D capabilities. With the implementation of robust incentive mechanisms and the steady development of a talent pipeline, the company’s patent-driven R&D initiatives are steadily advancing toward even higher standards.
Related Recommendations